Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-02
2005-08-02
Brumback, Brenda (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C530S326000
Reexamination Certificate
active
06924265
ABSTRACT:
The present invention relates to peptides and peptide analogues designed from HFE protein. In particular, it relates to peptides and peptide analogues designed from an alpha-1 region of HFE protein which lowers the binding affinity of transferrin receptor for transferrin. Such compounds mimic HFE protein function, and reduce iron uptake and/or accumulation by a cell.
REFERENCES:
patent: 5712098 (1998-01-01), Tsuchihashi et al.
patent: WO 97/38137 (1997-10-01), None
patent: WO 98/56814 (1998-12-01), None
“Computerized Drug Design. Still Promising. Not Yet Here”. Science. vol. 256. pp. 441 Apr. 24, 1992.
Ngo et al, ‘Computational Complexity, Potein Structure Prediction and the Levinthal Paradox’ The Protein holding Problem and Iertiary Structure Prediction Ed Me′zand. Le Grand BirkHauser Boston Ma, pp 491-495 1994.
Rudinger, J (1976) Peptide Hormones (ed. J.A. Parsons) University Park Press Baltimore pp 1-7.
Dadone et al., 1982, “Analysis of laboratory expression of the disease by genotype in 18 pedigrees”,Am. J. Clin. Pathol. 78:196-207.
Edwards et al., 1988, “Prevalence of Hemochromatosis Among 11,065 Presumably Healthy Blood Donors”,N. Engl. J. Med. 18:1355-1362.
Feder et al., 1998, “The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding”,Proc. Natl. Acad. Sci. U.S.A. 95:1472-1477.
Feder et al., 1996, “A novel MHC class l-like gene is mutated in patients with hereditary hemochromatosis”,Nature Genetics13:399-408.
Feder et al., 1997, “The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression”,J. Biol. Chem. 272: 14025-14028.
Gross et al., 1998, “Co-trafficking of HFE, a nonclassical major histocompatibility complex class 1 protein, with the transferrin receptor implies a role in intracellular iron regulation”,J. Biol. Chem273:22068-22074.
Kosbor et al., 1983, “The production of monoclonal antibodies from human lymphocytes”,Immunology Today4:72.
Lebron et al., 1998, “Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor”,Cell93:111-123.
McLaren et al., 1995, “Prevalence of heterozygotes for hemochromatosis in the white population of the United States”,Blood86:2021-2027.
Sampietro et al., 1998, “High prevalence of the His63 Asp HFE mutation in Italian patients with porphyria cutanea tarda”,Hepatology27:181-184.
Stagsted et al. 1993, “Amino acid residues essential for biological activity of a peptide derived from a major histocompatibility complex class 1 antigen”,Proc. Natl. Acad. Sci. U.S.A. 90 7586 7690.
Stagsted et al., 1990, “Regulation of insulin receptor functions by a peptide derived from a major histocompatibility complex class 1 antigen”,Cell62:297-307.
Van Landeghem et al., 1998, “Interaction between haemochromatosis and transferrin receptor genes in multiple myeloma”,Lancet352: 1285-1286.
Yaouang et al., 1997, “Hemochromatosis Cys282Tyr mutation in pyridoxine-responsive sideroblastic anaemia”,Lancer349:1475-1476.
Bennett Melanie
Bjorkman Pamela J.
Feder John N.
Lebron Jose
Schatzman Randall C.
Bio-Rad Laboratories, Inc.
Brumback Brenda
California Institute of Technology
Gupta Anish
Jones Day
LandOfFree
Peptides and peptide analogues designed from HFE protein and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides and peptide analogues designed from HFE protein and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and peptide analogues designed from HFE protein and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3454963